GILD
Stock Details
GILD is Gilead Sciences, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 62.00$. Average daily volumn in 3 months 8.03M. Market cap 78.65B
Stock symbol : GILD. Exchange : NasdaqGS. Currency : USD Lastest price : 62.70$. Total volume : 626.00k. Market state REGULAR Click reload if you want to check the lastest price on market!!!
Gilead Sciences, Inc. (GILD)
Last Price
62.70$Change
0.36Volume
626.00k
| Previous Close | 62.34 |
| Open | 62.62 |
| Day Range | 62.41-62.77 |
| Bid | 62.57 x 900 |
| Ask | 62.55 x 3.1k |
| Volume | 626k |
| Average Volume | 8.03M |
| Market Cap | 78.65B |
| Beta | 0.38 |
| 52 Week Range | 57.17-74.12 |
| Trailing P/E | 17.51 |
| Foward P/E | 9.92 |
| Dividend (Yield %) | 4.68% |
| Ex-Dividend Date | 2022-06-14 |
Financial Details
Organization
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of li... ver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Market Cap:
78.65BRevenue:
27.3BTotal Assets:
67.95BTotal Cash:
5.34B
News about "Gilead Sciences, Inc."
Gilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by AE Wealth Management LLC
Source from : Defense World - 3 days ago
AE Wealth Management LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 8.6% during the 1st quarter, HoldingsChannel.com reports. The firm owned 57,714 shares of the ...See details»
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Spire Wealth Management
Source from : Defense World - 5 days ago
Spire Wealth Management lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 16.5% during the first quarter, according to the company in its most recent disclosure with ...See details»
Is Gilead Sciences' Dividend Safe?
Source from : Nasdaq - 2 days ago
With this backdrop in mind, let's consider whether Gilead Sciences' dividend is safe. Gilead Sciences has been highly successful in the market for COVID-19 therapies thanks to its antiviral Veklury.See details»
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by MCIA Inc
Source from : ETF Daily News - 14 days ago
MCIA Inc trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 7.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 24,153 shares of ...See details»
Why Gilead Sciences Inc. (NASDAQ: GILD) Stock Might Be A Good Investment
Source from : stocksregister - 7 days ago
Gilead Sciences Inc. (NASDAQ:GILD) traded at $62.24 at last check on Wednesday, June 29, made an upward move of 0.05% on its previous day’s price. Looking at the stock we see that its previous close ...See details»
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
Source from : YAHOO!Finance - 9 days ago
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting ...See details»
How Florida clinics made millions by manipulating Gilead's free HIV drug program
Source from : The Business Journals - 8 days ago
A Florida health clinic agreed to pay $33 million to Gilead Sciences Inc. for its parts in a scheme to fraudulently prescribe and distribute a Gilead HIV prevention drug through a program designed to ...See details»
Gilead asks FDA again to approve twice-a-year HIV-fighting drug
Source from : The Business Journals - 8 days ago
Gilead Sciences Inc. is asking the Food and Drug Administration for the second time in a year to approve its experimental twice-a-year HIV-fighting drug lenacapavir. The FDA in February rejected the ...See details»
Carnegie Capital Asset Management LLC Cuts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
Source from : ETF Daily News - 11 days ago
Carnegie Capital Asset Management LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 5.1% in the first quarter, according to the company in its most recent ...See details»
Gilead: Kite's CAR T-cell Therapy Yescarta Gets EU Approval To Treat Relapsed Or Refractory FL
Source from : Nasdaq - 8 days ago
(GILD) announced Tuesday that its cell therapy company Kite's CAR T-cell therapy Yescarta (axicabtagene ciloleucel) received European marketing authorization from the European Commission to treat ...See details»
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
Source from : YAHOO!Finance - 7 days ago
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.See details»
Phase III data from Gilead’s hepatitis D ‘cure’ and Madrigal’s NASH hopeful take center stage at ILC
Source from : BioWorld - 8 days ago
New data confirming that Gilead Sciences Inc.’s Hepcludex (bulevirtide) effectively cures hepatitis delta virus (hepatitis D), one of the most severe viral infections of the liver, and favorable phase ...See details»
Gilead Sciences Inc ADR - Stock Ownership GILD34
Source from : Morningstar%2c Inc. - 5 days ago
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...See details»
Traders See Bumpy Road Ahead For Gilead Sciences
Source from : Benzinga.com - 13 days ago
Gilead Sciences, Inc. GILD climbed on Wednesday, even as the S&P 500 ended the day with losses. On CNBC's "Options Action," Tony Zhang said that Gilead Sciences traded nearly 2.5 times its average ...See details»